Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.

Area of Science:

• Biotechnology
• Molecular Biology
• Gene Therapy

Background:

• Gene therapy research is experiencing a resurgence, driven by advancements in gene delivery vector technology.
• Adeno-associated virus (AAV) has emerged as a prominent vector due to its non-enveloped structure and engineered DNA delivery capabilities.
• AAV vectors are particularly significant in clinical-stage experimental therapeutic strategies.

Purpose of the Study:

• To provide an overview of adeno-associated virus (AAV) as a gene therapy vector.
• To highlight key considerations for utilizing AAV in therapeutic applications.
• To discuss the safety and efficacy of AAV-based gene delivery strategies.

Main Methods:

• Review of current literature on adeno-associated virus (AAV) gene delivery.
• Analysis of recombinant AAV particle generation techniques.
• Evaluation of AAV's role in clinical-stage gene therapy trials.

Main Results:

• Recombinant AAV particles can be engineered to lack viral genes, enhancing safety.
• AAV vectors demonstrate potential for delivering specific DNA sequences to target cells.
• The use of AAV represents one of the safest strategies currently employed in gene therapies.

Conclusions:

• Adeno-associated virus (AAV) is a critical and safe vector for advancing gene therapy.
• Understanding AAV vector properties is essential for successful therapeutic development.
• AAV holds significant promise for future clinical applications in treating genetic disorders.